Baseline Ex Vivo and Molecular Responses of Plasmodium falciparum Isolates to Piperaquine before Implementation of Dihydroartemisinin-Piperaquine in Senegal

Dihydroartemisinin-piperaquine, which was registered in 2017 in Senegal, is not currently used as the first-line treatment against uncomplicated malaria. A total of 6.6% to 17.1% of P. falciparum isolates collected in Dakar in 2013 to 2015 showed ex vivo-reduced susceptibility to piperaquine. Neithe...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Antimicrob Agents Chemother
Main Authors: Robert, Marie Gladys, Foguim Tsombeng, Francis, Gendrot, Mathieu, Diawara, Silman, Madamet, Marylin, Kounta, Mame Bou, Wade, Khalifa Ababacar, Fall, Mansour, Gueye, Mamadou Wague, Benoit, Nicolas, Nakoulima, Aminata, Bercion, Raymond, Amalvict, Rémy, Fall, Bécaye, Wade, Boubacar, Diatta, Bakary, Pradines, Bruno
פורמט: Artigo
שפה:Inglês
יצא לאור: American Society for Microbiology 2019
נושאים:
Epidemiology and Surveillance
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC6496083/
https://ncbi.nlm.nih.gov/pubmed/30782997
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.02445-18
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים